Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Masjedi, M.R.
Right arrow Articles by Dokouhaki, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Masjedi, M.R.
Right arrow Articles by Dokouhaki, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Mutagenesis, Vol. 15, No. 6, 489-494, November 2000
© 2000 UK Environmental Mutagen Society/Oxford University Press

Chromosomal aberrations and micronuclei in lymphocytes of patients before and after exposure to anti-tuberculosis drugs

M.R. Masjedi2, A. Heidary1, F. Mohammadi, A.A. Velayati and P. Dokouhaki

National Research Institute of Tuberculosis and Lung Disease, Shaheed Beheshti University of Medical Sciences and Health Services, Darabad, Bahonar Avenue, Tehran and 1 Division of Radiobiology. National Radiation Protection Department, Atomic Energy Organization of Iran AEOI, PO Box 14155-4494, Tehran, Iran

To evaluate the genetic damage induced by tuberculosis infection and also by a combination of therapeutic exposure to anti-tuberculosis (anti-TB) drugs (isoniazid + rifampicin + pyrazinamide + ethambutol or streptomycin) we have considered chromosome aberrations (CA) and micronuclei (MN) in binucleate peripheral blood lymphocytes from 36 patients diagnosed with pulmonary tuberculosis prior to receiving anti-TB drugs in the first phase and in the second phase after 6 months of therapy with anti-TB drugs. The same cytogenetic study has also been performed on 36 healthy individual controls. It was shown that the frequencies of both CA and micronucleated binucleate cells increased significantly after therapy with anti-TB drugs as compared with TB patients and controls. In addition, we observed that both cytogenetic markers (CA and MN) in patients before treatment with anti-TB drugs were significantly (P < 0.05) higher than controls. No relationship was found between the frequency of MN and donor age. Thus, apart from drug effects, infection with tuberculosis is associated with increased CA and MN.

2 To whom correspondence should be addressed. Tel: +98 21 228 2111; Fax: +98 21 228 5777; Email: info{at}nritld.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 MutagenesisHome page
J. M. Battershill, K. Burnett, and S. Bull
Factors affecting the incidence of genotoxicity biomarkers in peripheral blood lymphocytes: impact on design of biomonitoring studies
Mutagenesis, November 1, 2008; 23(6): 423 - 437.
[Abstract] [Full Text] [PDF]

Home page
 BiometrikaHome page
P. R. Rosenbaum
Testing hypotheses in order
Biometrika, March 1, 2008; 95(1): 248 - 252.
[Abstract] [PDF]

Home page
 MutagenesisHome page
G. Gandhi and B. Singh
DNA damage studies in untreated and treated leprosy patients
Mutagenesis, November 1, 2004; 19(6): 483 - 488.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
A. K. Nersesyan
Re: Chromosomal aberration, micronucleus and Comet assays on peripheral blood lymphocytes of leprosy patients undergoing multidrug treatment (Mutagenesis, 17, 309-312, 2002)
Mutagenesis, May 1, 2003; 18(3): 307 - 307.
[Full Text] [PDF]

Home page
 MutagenesisHome page
K. Kalaiselvi, P. Rajaguru, M. Palanivel, M.V. Usharani, and G. Ramu
Chromosomal aberration, micronucleus and Comet assays on peripheral blood lymphocytes of leprosy patients undergoing multidrug treatment
Mutagenesis, July 1, 2002; 17(4): 309 - 312.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.